QuanMol

Platform-driven service world

Leaders in AI-powered molecular design

Quanmol Tech stands at the cutting edge of AI-powered small molecule discovery. We are focusing on the interaction of functional organic molecules with biomacromolecules and developing our proprietary QuanMol ReDefine platform, with the commitment to revolutionize the field with advanced platform technologies and interaction-based drug design (IBDD) as the new era of AI-driven small molecule precision design.

OUR TECHNOLOGY

QuanMol offers a cutting-edge in-silico molecular discovery platform, designed to provide unparalleled solutions in the field of molecular design.

At QuanMol, we have developed a revolutionary in-silico discovery platform, QuanMol ReDefine, that utilizes a pioneering integration of physics-informed deep learning and state-of-the-art computational chemistry methods. This innovative approach enables us to provide unparalleled, out-of-the-box solutions for pharmaceutical development, allowing for faster and more accurate drug discovery and development. We have designed it to be user-friendly and accessible, making it easy for researchers and pharmaceutical companies to access and utilize the powerful tools it provides.With QuanMol ReDefine, we are bringing the future of molecular design within reach.

OUR PRODUCTS

Accelerated molecular design

QuanMol Thinker

A revolutionary AI agent that empowers rational molecular design by providing unparalleled insights and decision-making capabilities.

QuanMol Unifier

A universal molecular representation platform that accurately predicts pharmaceutical properties, streamlining the drug development process.

QuanMol Navigator

A world-leading structure prediction engine for protein-ligand interactions, providing unparalleled accuracy and efficiency in identifying potential drug targets.

These products are the result of years of research and development, and are designed to provide researchers and pharmaceutical companies with the tools they need to make informed decisions and accelerate the drug discovery process.

OUR WORK

QuanMol in the news

BROWSE ALL >

Press Release — Jan 19,2023

QuanMol Signed Strategic Partnership Agreement with Pharma Data Provider Pharmacodia

Commencing the new year in 2023, Pharmacodia and QuanMol Tech together announced their strategic partnership agreement. This collaboration is grounded in their substantial resources in innovative drug R&D and the technological prowess of their platforms. Capitalizing on the potential inherent in AI and big data in drug development, the partners aim to synergize AI-driven designs for novel drug molecular structures and software systems optimizing drug properties. This strategic partnership, enriched by expert insights, seeks to catalyze advancements in the early stages of innovative drug discovery with the overarching objective of expediting the maturation of AI within the pharmaceutical domain and augmenting the success rates of drug development endeavors.

Press Release — Aug 22,2022

L’Oréal Announced QuanMol Tech as the BigBang Innovation Competition Awardee

QuanMol Tech has been named as one of the awardees for the 2022 BigBang Innovation Competition hosted by L’Oréal with a project that using QuanMol Tech’s unique ability of molecular simulation to predict organic compound’s optical properties. The BigBang aims to help L’Oréal better connect with startup companies that using advanced technologies to facilitate makeup industry development.

JOIN US

QuanMol is seeking talented professionals in artificial intelligence, computational chemistry, biology, and related disciplines. Join our team in shaping the future of molecular discovery!